Good morning, everyone, and welcome to the middle of the week. You made it this far, so why not forge ahead, yes? As for us, we are celebrating a gorgeous morning with some needed cups of stimulation. After the heat and humidity of the past few days, a sparkling sun and coooool breeze are quite welcome. And of course, we are happy to pass along the latest menu of tidbits to get you started on your way. Hope you have a smashing day, and do stay in touch. We accept documents and tips, you know. …
The industries that shepherd goods around the world on ships, planes, and trucks acknowledge they are not ready to handle the challenges of shipping an eventual Covid-19 vaccine from drug makers to billions of people, Bloomberg News explains. Already stretched thin by the pandemic, freight companies face shrinking capacity on container ships and cargo aircraft to a lack of clarity on when a vaccine will arrive. Shippers must upgrade old technology that will slow the relay race to transport fragile vials of medicine in unprecedented quantities.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
What is it?
STAT Plus is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
